SPRC SciSparc Ltd. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1611746 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2018Q2*2018-06-30 | 2017Q2*2017-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $650,000 | $455,000 |
| SG&A expense | $1.00M | $971,000 |
| Operating income | -$1.65M | -$1.43M |
| Interest expense | $1,000 | $437,000 |
| Net income | -$1.21M | -$1.86M |
| EBITDA | -$1.65M | -$1.43M |
| EPS (basic) | 0.01 | 0.03 |
| EPS (diluted) | 0.01 | 0.03 |
| Balance sheet | ||
| Cash & equivalents | $5.10M | $11.78M |
| Receivables | $448,000 | $242,000 |
| Current assets | $6.28M | $12.04M |
| PP&E, netmay include right-of-use assets (IFRS) | $53,000 | $17,000 |
| Total assets | $6.38M | $12.06M |
| Current liabilities | $1.23M | $671,000 |
| Total liabilities | $1.23M | $671,000 |
| Shareholders' equity | $5.15M | $11.38M |
| Cash flow statement | ||
| Operating cash flow | -$1.83M | -$1.90M |
| Capital expenditure | $3,000 | $7,000 |
| Free cash flow | -$1.84M | -$1.91M |
| Investing cash flow | -$503,000 | -$9,000 |
| Financing cash flow | $1,000 | $1.94M |
| Depreciation & amortization | $3,000 | $1,000 |
| Stock-based compensation | $138,000 | $71,000 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.